The Human mammary carcinoma marker CA15-3 (CA15-3) ELISA Kit is used to quantitatively measure the levels of CA15-3 in human serum and plasma. This assay employs the quantitative sandwich enzyme immunoassay technique, in which CEA in the samples or standards are sandwiched between pre-coated CA15-3 antibody and HRP-conjugated antibody specific for CA15-3. Following a wash to remove any unbound reagent, the TMB substrate solution is added to the wells and color develops in proportion to the amount of CA15-3 bound in the initial step. The color development is stopped and the intensity of the color is measured at 450 nm via a microplate reader. This kit displays many advantages, including sensitivity, specificity, precision, linearity, and recovery. The product instructions are access to more information.

CA15-3 is a serum-based product of the MUC1 gene. Some types of cancer cells release the CA 15-3 antigen into the blood. Among these cancers, breast cancer is the one most likely to release CA15-3, especially in breast cancer that relapses after treatment. CA15-3 is therefore the most widely used serum marker for breast cancer. Its preoperative concentrations predict poor prognosis in node-negative and node-positive breast cancer. Kurebayashi J et al. have revealed that CA15-3 may play a role in monitoring response to chemotherapy in locally advanced breast cancer (LABC). Duffy MJ et al. further verified the conjecture and suggested that the most important role for CA15-3 is to monitor therapy in patients with end-stage breast cancer